Latest News

 

Spotlight

 

Technology

09-03-15 Zogenix to Participate in the Wells Fargo 2015 Healthcare Conference
08-10-15 Zogenix Provides Corporate Update and Reports Second Quarter 2015 Financial Results
08-05-15 Zogenix Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

  Relday is a proprietary, once-monthly subcutaneous formulation of risperidone for treating schizophrenia. The Relday Multi-Dose study was initiated in January and results are anticipated in Q3 2015.

  DosePro is a first-in-class, easy-to-use drug delivery system designed for self-administration of a pre-filled, single dose of liquid drug, subcutaneously, without a needle. DosePro offers benefits to patients including instant, easy dosing, less anxiety over self-injection, no need for sharps disposal, no risk of needle stick injury or contamination, and reliable performance.